Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 2
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ov…
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Estimated
~$10 – $7,500
Roswell Park Cancer InstituteNCT05231122
Phase 2
A Phase 2 Randomized Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy
This is a phase II randomized study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, administered alone or in comb…
Ovarian Clear Cell CarcinomaMetastatic Ovarian CancerRecurrent Ovarian Clear Cell Adenocarcinoma
Estimated
~$10 – $6,250
Tufts Medical CenterNCT07718854
Phase 1
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer th…
Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more
Estimated
~$10 – $5,625
National Cancer Institute (NCI)NCT05950464
Phase 1
MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalph…
Fallopian Tube CarcinosarcomaPrimary Peritoneal CarcinosarcomaRecurrent Fallopian Tube Carcinoma+13 more
Estimated
~$10 – $6,250